Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sacituzumab govitecan

(SAK-ih-TOO-zoo-mab GOH-vih-TEE-kan)
A drug used to treat adults with certain types of breast cancer that have already been treated with other therapy. It is also being studied in the treatment of other types of cancer. Sacituzumab govitecan contains a monoclonal antibody called sacituzumab that binds to a protein called TROP2, which is found on some cancer cells. It also contains an anticancer drug called SN-38, which may help kill cancer cells. Sacituzumab govitecan is a type of antibody-drug conjugate. Also called Trodelvy.
More Information
Search NCI's Dictionary of Cancer Terms